Spravato
(Esketamine)ApprovedSmall molecule
Esketamine is used to treat severe depression, particularly in people who haven't responded well to other antidepressants, and to reduce suicidal thoughts in people in crisis.[2] Spravato is currently approved and in use across 43 indications[4].[1]
Spravato is one of 745 small molecule programs targeting Depressive Disorder. It is currently in Approved.
43
Indications
152
Total Trials
50
Active Trials
744
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
7
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 40 indications
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Spravato
WWim Janssens
Approved
Lexiscan
AstellasPreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Tc99m Sestamibi
MM.D. Anderson Cancer Center
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
Lapatinib Plus Capecitabine
GSKPreclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Esketamine25 trials
Show 22 more trials
Effect of Esketamine on Conscious State in Patients With pDoC
Recruiting·—·N/A·NCT06389344·116 enrolled
Esketamine and Butorphanol for Post-Lobectomy Pain
Completed·—·Phase 4·NCT06398834·223 enrolled
Intranasal Esketamine and Fentanyl for Pain in Minor Trauma
Unknown status·—·Phase 4·NCT03421275·105 enrolled
ED50 of Esketamine for Laser Treatment in Children
Unknown status·—·N/A·NCT06294639·40 enrolled
Treatment Resistant Depression15 trials
Show 12 more trials
Major Depressive Disorder10 trials
Show 7 more trials
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Recruiting·—·Phase 3·NCT05603104·1,254 enrolled
Sedation5 trials
Show 2 more trials
Delirium4 trials
72 more indications
Depression4 trials
Personalized DBS Targeting for Treating Depression
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06784388·5 enrolled
Anxiety4 trials
Dexmedetomidine4 trials
Hepatocellular Carcinoma2 trials
Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 4·NCT05416073·70 enrolled
Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma
Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 4·NCT05670561·60 enrolled
Hemodynamic Stability2 trials
Breast Cancer2 trials
Post Operative Pain2 trials
Thoracoscopic Surgery2 trials
Septic Shock2 trials
Postpartum Depression2 trials
Suicide2 trials
Major Depression2 trials
Acute Pain2 trials
ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects
Recruiting·—·Phase 4·NCT06853041·74 enrolled
Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial
Terminated·AAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Phase 3·NCT06051227·235 enrolled
Effectiveness1 trial
The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy
Unknown status·FFirst Affiliated Hospital of Chongqing Medical University·Phase 1·NCT04777110·396 enrolled
Renal Impairment1 trial
Depressive Symptoms1 trial
Esketamine and Perioperative Depressive Symptoms
Completed·—·Phase 2/3·NCT04425473·435 enrolled
Thoracic Paravertebral Block1 trial
Anesthesia1 trial
Effects of Esketamine on Recovery of Consciousness After Propofol Anesthesia
Recruiting·—·N/A·NCT06430645·150 enrolled
Suicidality1 trial
Esketamine vs ECT for Acute Suicidality
Completed·—·N/A·NCT06355180·340 enrolled
Postoperative Pain Relief1 trial
Cardiac Surgery1 trial
Painless Gastrointestinal Endoscopy1 trial
Effect of Low-dose Esketamine Combined With Target-controlled Infusion of Propofol for Painless Gastrointestinal Endoscopy
Unknown status·—·N/A·NCT04691076·1,000 enrolled
Ovarian Cancer1 trial
Postoperative Sleep Disturbance1 trial
Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery
Recruiting·—·N/A·NCT06451627·156 enrolled
Bariatric Surgery1 trial
Cesarean Section1 trial
Scoliosis1 trial
Gastrointestinal Function1 trial
Postoperative Recovery1 trial
Obesity1 trial
Critically Ill Patients1 trial
Postherpetic Neuralgia1 trial
The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04664530·48 enrolled
Hepatic Impairment1 trial
Quadratus Lumborum Block1 trial
Pain After Surgery1 trial
Valve Surgery1 trial
Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery
Completed·—·N/A·NCT06608030·142 enrolled
Cognitive Function1 trial
Treatment Resistant Depression (TRD)1 trial
Parkinson's Disease1 trial
Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease
Recruiting·—·N/A·NCT06543563·102 enrolled
Efficacy and Safety1 trial
Cardiac Repolarization1 trial
Attention1 trial
Post-Traumatic Stress Disorder1 trial
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT06795659·4 enrolled
Spinal Cord Injury1 trial
Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury
Not yet recruiting·—·N/A·NCT06531837·60 enrolled
Abuse Potential1 trial
Inflammatory Bowel Disease1 trial
Allergic Rhinitis1 trial
Intraoperative1 trial
Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04682782·26 enrolled
Postoperative Quality of Recovery1 trial
Autism Spectrum Disorder1 trial
Depressive Disorder, Major1 trial
Depth of Anesthesia1 trial
Suicidal Ideation1 trial
Endometriosis1 trial
Emergence Agitation1 trial
Intensive Care Unit1 trial
Laparoscopic Cholecystectomy1 trial
Irritable Bowel Syndrome1 trial
Pruritus1 trial
The Effect of Intraoperative Infusion of Esketamine on Cholestatic Pruritus in Patients Undergoing Hepatobiliary Surgery: A Single-center Randomized Controlled Study
Not yet recruiting·TTianjin Medical University General Hospital·Preclinical·NCT07760740·100 enrolled
Adverse Respiratory Events1 trial
A Comparative Study on the Incidence of Respiratory Adverse Events Between Esketamine Combined With Remazolam and Traditional Propofol in Pediatric Gastroscopy
Not yet recruiting·SSecond Affiliated Hospital of Wenzhou Medical University·Approved·NCT07748884·120 enrolled
Biliary Tract Disease1 trial
Old Age1 trial
Regulatory
FDA Approval Timeline[5]
Mar 5, 2019
SPRAVATO
NDA NDA211243
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Spravato drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Esketamine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glutamate [NMDA] Receptor Negative Allosteric Modulator[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens